Kusatsu/Shiga, Japan — May 23, 2017– Takara Bio Inc. announces that HF10 US Phase II clinical trial data will be presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (June 2-6, 2017, Chicago, Illinois, U.S.)

【Outline of presentation】

Name of conference ASCO(American Society of Clinical Oncology) Annual Meeting 2017
Place McCormick Place (Chicago, Illinois, U.S.)

June 3 
13:15-16:45(Poster session) 
16:45-18:00(Poster discussion session)

Title Final results of Phase II multicenter trial of HF10, a replication-competent HSV-1 Oncolytic Virus, and Ipilimumab combination treatment in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma

The final results of Phase II clinical trial for oncolytic virus HF10 in the U.S.


Enrollment: Of 46pts enrolled and treated: 37% IV; 43% with ≥ 1 prior cancer therapy for unresectable/metastatic melanoma.

Safety: Most HF10-related AEs were ≤G2, similar to HF10 monotherapy. No DLTs were reported.

Efficacy: Of the 44 efficacy evaluable pts, BORR at 24 weeks was 41%; disease stability rate was 68%. As of Feb 06, 2017, median PFS was 19 months and median overall survival was 21.8 months.

Conclusions: The combination HF10 and ipilimumab treatment demonstrated a more favorable benefit/risk profile than Ipilimumab alone. It suggests that it would be a potential novel therapeutic approach for metastatic melanoma.

Poster Presentation

Click here for the poster